CGT Global

For nearly two decades CGT Global has pursued our mission to transform healthcare. We accelerate cell and gene therapy research and clinical trials, we streamline the commercialization of new treatments, and now, we are traversing the last mile to patient access to life-changing remedies. Accelerating Research and Clinical Trials: CGT Global is a leading manufacturer of fresh and cryopreserved human primary cells, bone marrow, cord blood, peripheral blood and disease state products. With a national footprint of CGT Clinics and Laboratories, a worldwide distribution network and over 40 partner hospitals across the United States, CGT Global is uniquely aligned for solutions and scalability. Our huge national pool of highly vetted, diverse, and recallable donors supports the most exacting research and clinical trial requirements. Streamlining the Commercialization of New Treatments Efficiently scaling newly approved and commercialized cell and gene therapies is a huge challenge to equitable healthcare worldwide. We support patients from regional healthcare facilities and directly from pharmaceutical companies by manufacturing and administering therapies and managing logistics -- from cell collection, modification, expansion and infusion for both autologous and allogeneic therapies. Traversing The Last Mile To The Patient Administering cell and gene therapies requires specialized regulatory compliance, specific certifications, focused patient collection and treatment facilities, costly logistical capabilities, and precise training for staff. Taken all together, the ability to collect, modify, store and infuse in the same facility is an enormous and crucial step in traversing the last mile to patient access. We are proud of our mission. By innovating each stage of the treatment development and delivery cycle, CGT Global gives precious months and years back to those facing serious medical conditions. #celltherapy #genetherapy #primarycells #immunotherapy